#ASH20 In a multiple myeloma showdown, Regeneron marches out new PhI data for its BCMA bispecific
After kicking off a multiple myeloma rivalry with Bristol Myers Squibb at last year’s ASH, Regeneron is back with an updated safety and durability analysis from the first-in-human study of its BCMA bispecific.
In the Phase I portion of a Phase I/II dose-escalation study, researchers noted a 6-month median duration of response, Regeneron announced at ASH 2020. “We feel very encouraged,” Andres Sirulnik, senior VP of translational and clinical sciences and hematology, said of REGN5458. “The drug is very well tolerated.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.